



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

February 15, 2007

Docket No. 03008485
Control No. 139821

License No. 45-15048-01

Timothy Taylor, M.D.
Radiation Safety Officer
Retreat Hospital, Inc.
2621 Grove Avenue
Richmond, VA 23220

SUBJECT: RETREAT HOSPITAL, INC., LICENSE AMENDMENT, CONTROL NO. 139821

Dear Dr. Taylor:

This refers to your license amendment request. Enclosed with this letter is the amended license adding Dr. Aggarwal and removing Dr. Cockrell. As discussed with the Radiation Safety Office at Boston University Medical Center, Dr. Aggarwal performed diagnostic studies and iodine therapy treatments under a permit issued to Dr. Oates. Therefore, Dr. Aggarwal has been approved for 10 CFR 31.11, 35.100, 35.200, and iodine diagnostic and therapeutic uses only. If you require further 10 CFR 35.300 uses for Dr. Aggarwal, you may submit a separate amendment request documenting training and experience with additional therapeutic radionuclides. In addition, please note that Dr. Aggarwal's first name has been spelled Atul, consistent with the spelling on his medical license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Toolkit Index Page**. Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

T. Taylor
Retreat Hospital, Inc.

2

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 43

T. Taylor
Retreat Hospital, Inc.

3

DOCUMENT NAME: C:\FileNet\ML070530399.wpd

SUNSI Review Complete: PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	☐ N	DNMS/RI	☐	DNMS/RI	☐		☐
NAME	PLanzisera / PAN /							
DATE	2/15/07							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Retreat Hospital, Inc. 2. 2621 Grove Avenue Richmond, Virginia 23220	In accordance with the letter dated November 28, 2006, 3. License number 45-15048-01 is amended in its entirety to read as follows: 4. Expiration date May 31, 2014 5. Docket No. 030-08485 Reference No.
---	---

- | | | |
|---|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc. Model STM 1251)</p> <p>E. Prepackaged Kits</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 300 millicuries</p> <p>D. 1 curie</p> <p>E. 3 millicuries</p> |
|---|---|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.
- E. *In vitro* studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-15048-01Docket or Reference Number
030-08485

Amendment No. 43

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 2621 Grove Avenue, Richmond, Virginia.
11. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

James J. Zelenak, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Maurice F. Mullins, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
B. Gerald Yount, Jr., M.D.	35.100; 35.200; <i>in vitro</i> studies
George W. Martin, M.D.	35.100; 35.200; Oral administration of sodium iodide Iodine-131 in quantities less than or equal to 33 millicuries; <i>in vitro</i> studies
Efstathios Spinos, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Joel F. Parker, M.D.	35.100; 35.200; <i>in vitro</i> studies
Scott Cunningham, M.D.	35.100; 35.200; <i>in vitro</i> studies
Timothy R. Taylor, M.D.	35.100; 35.200; <i>in vitro</i> studies
Ray A. Beauchamp, M.D.	35.100; 35.200; <i>in vitro</i> studies
R. West Fuller, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
W. Powell Baker, M.D.	35.100; 35.200; <i>in vitro</i> studies
J. Keith Thompson, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Jeffrey E. Hull, M.D.	35.100; 35.200; <i>in vitro</i> studies
Brian R. J. Williamson, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Vasundhara Raval, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Russell O. Briere, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies
Gerry Lee Reece, M.D.	35.100; 35.200; 35.300; <i>in vitro</i> studies

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-15048-01Docket or Reference Number
030-08485

Amendment No. 43

Authorized UsersMaterial and Use

Kiernan Cross, M.D.

35.100; 35.200; *in vitro* studies

Melanie Fidler, M.D.

35.100; 35.200; *in vitro* studies

Robert Fidler, M.D.

35.100; 35.200; *in vitro* studies

Michele Lajaunie, M.D.

35.100; 35.200; *in vitro* studies

Bernard Tisdale, M.D.

35.400

David Randolph, M.D.

35.400

Atul Aggarwal, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131; *in vitro* studies

12. The Radiation Safety Officer for this license is Timothy Taylor, M.D.
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-15048-01Docket or Reference Number
030-08485

Amendment No. 43

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 15, 2003 (ML033630048)
- B. Letter dated July 27, 2005 (ML052170155)
- C. Letter dated February 14, 2006 (ML060740331)
- D. Letter dated April 19, 2006 (ML061170587)
- E. Letter dated October 25, 2006 (ML0630070556)
- F. Letter received October 26, 2006 (ML63120490)



For the U.S. Nuclear Regulatory Commission

Date February 15, 2007

By

Original signed by Penny Lanzisera

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406